Aktiesnakken — Februar 2011
-
Så kører topotarget!
-
CEO der kommer fra Merck
-
Slide takeoff 2011
-
Joint development med spectrum
-
Blockbuster potential
-
Focus på belinostat
-
Divested totect
-
Belinostat - nu
-
Best in class safety
-
3 indixationer gennemgåes
-
Først PTCL
-
12 tusind nye pts.
-
Fda fast track
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind